Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
November 07 2024 - 7:00AM
Alvotech (NASDAQ: ALVO), a global biotech company specializing in
the development and manufacture of biosimilar medicines for
patients worldwide, announced today its participation in Citi’s
2024 Global Healthcare Conference in Miami, Florida on December 4,
2024, and in Evercore’s HealthCONx Conference in Coral Gables,
Florida on December 5, 2024. Members of the management team will
host one-on-one meetings at both conferences. Alvotech will also
hold a fire-side chat at Evercore’s HealthCONx Conference on
Thursday, December 5, 2024 starting at 12:55 ET (17:55 GMT).
A live audio webcast of Alvotech’s fire-side
chat at the Evercore HealthCONx Conference will be available to
investors and the general public. Registration information for the
audio webcast is available in the Investors Section of Alvotech’s
website under News and Events – Events and Presentations. After the
event, an audio recording of the event will be available for the
next 90 days.
About AlvotechAlvotech is a
biotech company, founded by Robert Wessman, focused solely on the
development and manufacture of biosimilar medicines for patients
worldwide. Alvotech seeks to be a global leader in the biosimilar
space by delivering high quality, cost-effective products, and
services, enabled by a fully integrated approach and broad in-house
capabilities. Alvotech has launched two biosimilars. The current
development pipeline includes nine disclosed biosimilar candidates
aimed at treating autoimmune disorders, eye disorders,
osteoporosis, respiratory disease, and cancer. Alvotech has formed
a network of strategic commercial partnerships to provide global
reach and leverage local expertise in markets that include the
United States, Europe, Japan, China, and other Asian countries and
large parts of South America, Africa and the Middle East.
Alvotech’s commercial partners include Teva Pharmaceuticals, a US
affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA
Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma
(EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr.
Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med
Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma
Corporation (Canada), Yangtze River Pharmaceutical (Group) Co.,
Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia,
Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding
LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada
Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin
America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam,
Philippines, and South Korea). Each commercial partnership covers a
unique set of product(s) and territories. Except as specifically
set forth therein, Alvotech disclaims responsibility for the
content of periodic filings, disclosures and other reports made
available by its partners. For more information, please visit
www.alvotech.com.
Please visit our investor portal, and our website
or follow us on social media on LinkedIn, Facebook, Instagram, X
and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL
COMMUNICATIONS Benedikt Stefansson,
VPalvotech.ir@alvotech.com
Alvontech (NASDAQ:ALVO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Alvontech (NASDAQ:ALVO)
Historical Stock Chart
From Dec 2023 to Dec 2024